GAPDH and cholangiocarcinoma: In the animal experiments, the dramatic reduction of some conventionally used protein markers including GAPDH, tubulin, cyclophilin B and cofilin in CCA progression was unexpectedly found in HuCCT1 tumors treated with a high dose of dasatinib (Figure 4).